A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 230
Summary
- Conditions
- Epithelial Ovarian Cancer
- Advanced or Metastatic Solid Tumors
- Squamous Cell Carcinoma of the Head and Neck
- Cervical Carcinoma
- Small Cell Lung Carcinoma
- Squamous Cell Anal Cancer
- Fallopian Tube Cancer
- Gastric or Gastroesophageal Junction Adenocarcinoma
- Hepatocellular Carcinoma
- Triple -Negative Breast Cancer
- Renal Cell Carcinoma
- Squamous Cell Vulvar Carcinoma
- Urothelial Carcinoma
- Primary Peritoneal Carcinoma
- Prostate Carcinoma
- Non Small Cell Lung Carcinoma
- Intrahepatic Cholangiocarcinoma
- Melanoma
- Pancreatic Carcinoma
- Squamous Cell Penile Carcinoma
- Mismatch Repair Deficiency
- MSI-H
- Nasopharyngeal Carcinoma
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03849469
- Collaborators
- ICON Clinical Research
- Investigators
- Study Director: Benjamin Thompson, MD, PhD Xencor, Inc.
Get Well Soon